Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study focuses on individuals living with Type 1 Diabetes Mellitus, a condition where the body does not produce insulin, which is a hormone needed to regulate blood sugar. A common challenge for people with this condition is hypoglycemia, which occurs when blood sugar levels drop too low, often during physical activity. The purpose of the study is to evaluate whether using a low dose of dasiglucagon or glucagon can help prevent or reduce these dangerous drops in blood sugar levels during and after exercise.
Participants in the study will use an automated insulin delivery system, which is a technology that helps manage insulin levels automatically. During the study, individuals will receive a subcutaneous injection, meaning the medicine is injected just under the skin, before performing moderate exercise. The study examines how these medications affect blood sugar levels while performing continuous exercise approximately 90 minutes after eating a meal.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
10 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an injection used to help raise blood sugar levels. It works by telling the liver to release stored sugar into the bloodstream, which helps prevent dangerously low blood sugar levels.
is an injection used to treat very low blood sugar. Similar to other glucagon products, it works by stimulating the liver to release glucose into the blood to quickly increase sugar levels.
This medication is given as a shot under the skin using a pre-filled syringe. It is currently being studied for its ability to help manage blood sugar levels in people with type 1 diabetes. When injected, it works by signaling the liver to release stored sugar into the bloodstream to prevent dangerously low blood sugar levels. It belongs to a group of medicines known as glycogenolytic hormones.
This medicine is administered through a subcutaneous injection using a powder and liquid kit that is mixed before use. It is a well-established treatment used to quickly raise blood sugar levels during emergencies. At a molecular level, it works by stimulating the liver to break down stored sugar and release it into the body. It is pharmacologically classified as a glycogenolytic hormone.
Other trials in this disease – keep exploring while you decide
Austria
The Netherlands
Italy
DenmarkDenmark
Swedensourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.
